Receive The Newest Study Notifications

The PROOF trial, a Phase 3 trial of infigratinib in first-line cholangiocarcinoma, is currently enrolling SAN FRANCISCO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary QED Therapeutics announced today that it has secured both Fast...

Next-Generation Cardiac Myosin Inhibitor Advances In Clinical Trial Designed to Assess Effects Using Two-Week Dose Titration Schedule SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that...

WALTHAM, MA / ACCESSWIRE / January 6, 2020 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed enrollment in its follow-on...

Single Dose Resulted in Sustained Mean Reduction of 96% in Bleed Rates at 6e13 vg/kg Dose in Third Year Completely Eliminated Prophylactic Factor VIII Use in 6e13 vg/kg and 4e13 vg/kg Doses 2nd Publication in NEJM on Valoctocogene Roxaparvovec SAN RAFAEL, Calif., Jan....

NESS ZIONA, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (SLGL) today announced the initiation of a Phase 1 proof of concept clinical study of SGT-210, its novel, topical, epidermal growth factor receptor inhibitor in patients with punctate...

Trial to assess safety and tolerability of mavorixafor in combination with ibrutinib in WM patients with MYD88/CXCR4 double mutation associated with treatment resistance CAMBRIDGE, MA, UNITED STATES - Dec 30, 2019 - X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a...

BOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, announced that in December the company completed patient enrollment in its Phase 3 study of the...

- GRAVITAS-301 results show that treatment with itacitinib in combination with corticosteroids did not statistically improve overall response rate or non-relapse mortality compared to placebo plus corticosteroids WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation...

CUPERTINO, Calif., Jan. 2, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis. Twenty-two patients completed the study, applying DUR-928...

A study published today in STEM CELLS Translational Medicine indicates that treating cryptoglandular perianal fistula with autologous adipose-derived stem cells (ASCs) is safe and can in fact promote long-term and sustained healing. The FISPAC Collaborative Group A...

Pivotal Phase 2/3 study is being conducted in collaboration with Children's Oncology Group DUBLIN, Dec. 30, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in the pivotal Phase 2/3 clinical study...

A newly approved Chinese drug for Alzheimer’s will start clinical trials in the US and Europe next year as the country’s first novel therapy for the incurable disease seeks global legitimacy. Shanghai Green Valley Pharmaceutical Co. plans to recruit around 2,046...

Santa Ana, CA -- (SBWIRE) -- 12/30/2019 -- Technological advancements have allowed medicial sciences to flourish. More and more studies are being conducted on a daily basis to discover novel ways of preventing, detecting, diagnosing, controlling, and treating...

INDIANAPOLIS, Dec. 30, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the opening of the LIBRETTO-531 clinical trial [NCT04211337] for selpercatinib, also known as LOXO-292, for treatment-naïve RET-mutant medullary thyroid cancer (MTC)...

SOUTH SAN FRANCISCO, Calif., Dec. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immune-mediated...

(Bloomberg) — A newly approved Chinese drug for Alzheimer’s will start clinical trials in the U.S. and Europe next year as the country’s first novel therapy for the incurable disease seeks global legitimacy. Shanghai Green Valley Pharmaceutical Co. plans to recruit...

MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announced that the first patient has been dosed in a phase 1b clinical study of MorphoSys' proprietary human anti-CD19 antibody tafasitamab in newly diagnosed diffuse large B cell...

Selpercatinib (LOXO-292) will be compared with the standard of care in the first ever phase III clinical trial in patients with advanced or metastatic treatment-naïve RET fusion-positive non–small cell lung cancer (NSCLC), according to a press release from Eli Lilly...

Starpharma (ASX:SPL, OTCQX:SPHRY) today announced that AstraZeneca (LSE/STO/NYSE:AZN) has commenced a phase 1 clinical trial of AZD0466 (DEP ® Bcl2/xL conjugate) and the first patient has been successfully dosed. The trial will recruit patients with a range of cancers...

NEW YORK, Dec. 24, 2019 /PRNewswire/ -- Clinical trials recruitment agencies aim to achieve multiple goals, including attracting potential candidates. One of the ways that this can be done is through social media, Instagram being one of the most unique platforms. If...